Acquist Therapeutics Expands Patent Portfolio for Novel Small Molecules, Receives Fourth U.S. Composition Patent

New Drugs Target Under-Served Patients and Multiple Inflammatory Diseases

News provided by

Acquist Therapeutics, Inc.

21 Apr, 2020, 08:05 ET

CHATHAM, N.J., April 21, 2020 /PRNewswire/ -- Acquist Therapeutics, Inc., a biopharmaceutical company committed to discovery of new treatments for people with inflammatory diseases, today announced that the Company received a fourth patent from the U.S. Patent Office that covers the Acquist investigational drug library. The patent covers compounds that are intended to help patients with gout, NASH (nonalcoholic steatohepatitis), and other illnesses.

Compositions, uses, and claims of this patent – 2019/0117654 A1 – have also been filed worldwide.  Collectively, the four U.S. patents cover more than 100 novel compounds, which the company believes will provide composition exclusivity to 2039.

The Company's lead clinical drug (ACQT1127) is a small molecule that is being developed for oral administration and once-daily dosing.  Acquist intends to prioritize its clinical program in patients with gout, along with a discovery program in selected patients with NASH.

Acquist Discovery

Acquist has developed novel, potent, bifunctional inhibitors of enzymes that reduce production and promote excretion of uric acid (UA).  This target is causally linked to many inflammatory diseases and is a primary initiator of gout.  In NASH, elevated UA is associated with fatty liver and subsequent triggering of inflammation.  In human liver cells, ACQT1127 sharply reduces both UA and triglycerides, and it normalizes enzyme activity targeted by other drugs that are currently in NASH clinical trials.

About Acquist

Acquist is focused on improving health for patients with inflammatory and metabolic diseases. Acquist compounds are markedly more potent than drugs currently used for gout.  A prototype drug with bifunctional activity has demonstrated exceptional clinical activity in reducing serum uric acid. In both NASH and gout, effective treatment could substantially relieve both morbidity and mortality from these progressive illnesses. Further information can be accessed at www.acquistrx.com.

Contacts:

Miriam Miller
Tiberend Strategic Advisors
[email protected]  

SOURCE Acquist Therapeutics, Inc.

Related Links

http://www.acquistrx.com

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.